This could be a very interesting finding for those who are wondering if we have CP or IC or whether CP/CPPS & IC are the same thing.
To a layperson like myself, it appears that the study shows a clear method of distiguishing CP from IC using just urine samples, which sounds like great news!
But what's not clear to me is whether an invasive procedure is involved. For instance what is meant by 'H-thymidine incorporation into primary normal adult human bladder epithelial cells'?
And most importantly, how significant is this study anyway?
Urology. 2004 Jan;63(1):22-6.
Antiproliferative factor, heparin-binding epidermal growth factor-like
growth factor, and epidermal growth factor in men with interstitial
cystitis versus chronic pelvic pain syndrome.
Keay S, Zhang CO, Chai T, Warren J, Koch K, Grkovic D, Colville H,
Alexander R.
Division of Infectious Diseases, Department of Medicine, University of
Maryland School of Medicine, Baltimore, Maryland, USA.
OBJECTIVES: To determine whether men with chronic prostatitis/chronic
pelvic pain syndrome (CP/CPPS) have urine markers previously described
for patients with interstitial cystitis (IC; presence of
antiproliferative factor [APF] activity, decreased levels of
heparin-binding epidermal growth factor-like growth factor [HB-EGF],
and increased levels of epidermal growth factor). METHODS: Clean catch
urine specimens were collected from 41 symptomatic patients with
CP/CPPS, 36 asymptomatic men without bladder disease who served as the
control group, and 24 men with IC. APF activity was determined by
(3)H-thymidine incorporation into primary normal adult human bladder
epithelial cells. HB-EGF and epidermal growth factor levels were
determined by enzyme-linked immunosorbent assay. RESULTS: Men with
CP/CPPS did not differ significantly from asymptomatic controls for
any of the three markers tested (P >0.49). In contrast, APF activity
was present significantly more often and HB-EGF levels were
significantly lower in the urine specimens from men with IC than in
the specimens from controls or patients with CP/CPPS (P <0.00001 for
all four comparisons). Although the epidermal growth factor levels
also tended to be higher in the urine from patients with IC than in
the urine from controls, the difference did not reach statistical
significance (P = 0.06). CONCLUSIONS: These findings indicate that at
least two of the urine biomarkers previously identified in women with
IC (presence of APF activity and decreased levels of HB-EGF) are also
found in men with IC, but not in men with CP/CPPS. This finding
suggests that IC and CP/CPPS may be two different disorders with
distinct pathophysiologies. It also confirms the utility of the
presence of APF activity and HB-EGF levels as markers for IC in men,
as well as in women, with this disorder.




